A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

A “Tag-and-Modify” Approach to Site-Selective Protein Modification

(2011) Justin M. Chalker et al.   ACCOUNTS OF CHEMICAL RESEARCH

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

(2011) A Palumbo et al.   BRITISH JOURNAL OF CANCER

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

(2011) Katharina Frey et al.   Integrative Biology

Site-Specific and Stoichiometric Conjugation of Cationic Porphyrins to Antiangiogenic Monoclonal Antibodies

(2010) Cristina M. A. Alonso et al.   BIOCONJUGATE CHEMISTRY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody drug-conjugates targeting the tumor vasculature

(2010) Hans-Peter Gerber et al.   mAbs

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

Chemical Modification of Proteins at Cysteine: Opportunities in Chemistry and Biology

(2009) Justin M. Chalker et al.   Chemistry-An Asian Journal

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH